Atlas Trials

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

Clinical trial NCT03810066 · COMPLETED

Trial details

NCT number
NCT03810066
Sponsor
University Hospital, Essen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLCEGFR T790MFDG-PET
Start date
2019-06-03
Primary completion
2021-12-31
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.